Effect of allopurinol and other xanthine oxidase inhibitors on oxidative stress in Alzheimer’s disease: A systematic review and meta-analysis (2015–2025)
Keywords:
Allopurinol, Febuxostat, Cognitive decline, Dementia prevention, Neuroprotection, Reactive oxygen species, Neurodegeneration, Uric acidAbstract
Background: Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline and neuropathology. Accumulating evidence implicates oxidative stress in AD pathogenesis. Xanthine oxidase (XO) is a major enzymatic source of reactive oxygen species in purine metabolism. XO inhibitors (e.g., allopurinol, febuxostat, topiroxostat) reduce XO-derived radicals and may thus ameliorate oxidative damage in the brain. We aimed to systematically review preclinical and clinical studies from 2015–2025 examining whether XO inhibition reduces oxidative stress markers, improves cognitive outcomes, or lowers dementia risk in AD. Methods: We searched PubMed, Scopus, Web of Science, and Google Scholar (2015–2025) using keywords combining “Alzheimer OR dementia” with “xanthine oxidase OR allopurinol OR febuxostat OR topiroxostat” and “oxidative stress OR cognitive OR dementia incidence”. Inclusion criteria were English-language studies on AD or related dementia assessing XO inhibitor effects on oxidative stress biomarkers, cognitive performance, or dementia incidence. We included both preclinical (animal in vitro experiments and in vivo models) and clinical (observational or interventional) studies. Screening, data extraction, and bias assessments (SYRCLE for animal studies, Newcastle–Ottawa Scale for observational studies, Cochrane tools for trials) were performed by two independent reviewers (blinded as XX and YY). A PRISMA flow diagram was constructed to map study selection.
Downloads
References
Alenezi A, Ahmad M, Ayyoub I, et al. (2024). Possible effect of allopurinol on risk of dementia: an updated meta-analysis. Research Square (preprint). DOI: 10.21203/rs.3.rs-5114989/v1 DOI: https://doi.org/10.21203/rs.3.rs-5114989/v1
Burrage EN, Prabhu SS, Oudomvilay C, et al. (2023). Psychosocial stress accelerates Alzheimer’s disease progression via the xanthine oxidase pathway. Physiology 38(Suppl 1):5731121. DOI: 10.1152/physiol.2023.38.S1.5731121 DOI: https://doi.org/10.1152/physiol.2023.38.S1.5731121
Butterfield DA, Halliwell B (2019). Oxidative stress in Alzheimer disease: mechanisms and consequences. Oxidative Medicine and Cellular Longevity 2019:5278186. DOI: 10.1155/2019/5278186
Chuang T-J, Wang Y-H, Wei JCC, Yeh C-J (2021). Association between use of anti-gout preparations and dementia in gout patients: a nationwide population-based study. Frontiers in Medicine (Lausanne) 8:607808. DOI: 10.3389/fmed.2020.607808 DOI: https://doi.org/10.3389/fmed.2020.607808
Johnson RJ, Kang DH, Feig DI, et al. (2018). Hyperuricemia, XO and neurodegenerative disorders: basic mechanisms and therapeutic implications. Current Rheumatology Reports 20(2):11. DOI: 10.1007/s11926-018-0713-9 DOI: https://doi.org/10.1007/s11926-018-0713-9
Lai SW, Hwang BF, Kuo YH, et al. (2022). Allopurinol use and the risk of dementia: a meta-analysis of case–control studies. Medicine (Baltimore) 101(26):e29827. DOI: 10.1097/MD.0000000000029827 DOI: https://doi.org/10.1097/MD.0000000000029827
Lara DR, Dall’Igna OP, Ghisolfi ES, Brunstein MG (2003). Allopurinol for the treatment of aggressive behavior in patients with dementia: a randomized, placebo-controlled clinical trial. International Clinical Psychopharmacology 18(1):53–55. DOI: 10.1097/00004850-200301000-00009 DOI: https://doi.org/10.1097/00004850-200301000-00009
Molet-Benhamou L, Giudici KV, et al. (2022). Association between urate-lowering therapies and cognitive decline in community-dwelling older adults: a post-hoc analysis of the MAPT study. Scientific Reports 12:15299. DOI: 10.1038/s41598-022-17808-6 DOI: https://doi.org/10.21203/rs.3.rs-699328/v2
Prabhu SS, Nolan VG, Burrage EN, et al. (2023). Psychosocial stress accelerates Alzheimer’s disease progression via the xanthine oxidase pathway (Abstract). Physiology 38(S1):abstr. DOI: 10.1152/physiol.2023.38.S1 DOI: https://doi.org/10.1152/physiol.2023.38.S1.5730102
Shadab R, Taha M, Khan KM, et al. (2024). Exploring the potential of allopurinol in dementia of Alzheimer’s type (STZ-induced) (Abstract). Alzheimer’s & Dementia 20(S4):e087850. DOI: 10.1002/alz.087850 DOI: https://doi.org/10.1002/alz.087850
Sies H, Berndt C, Jones DP (2017). Oxidative stress and Alzheimer’s disease: an overview. Neurochemistry International 110:76–83. DOI: 10.1016/j.neuint.2017.06.005 DOI: https://doi.org/10.1016/j.neuint.2017.06.005
Singh JA, Cleveland JD (2018). Comparative effectiveness of allopurinol versus febuxostat for preventing incident dementia in older adults. Arthritis Research & Therapy 20(1):167. DOI: 10.1186/s13075-018-1663-3 DOI: https://doi.org/10.1186/s13075-018-1663-3
Song Y, Racette BA, Camacho-Soto A, Searles Nielsen S (2023). Biologic targets of prescription medications and risk of neurodegenerative disease in US Medicare beneficiaries. PLOS ONE 18(5):e0285011. DOI: 10.1371/journal.pone.0285011 DOI: https://doi.org/10.1371/journal.pone.0285011
Takahashi K, Mizukami H, Osonoi S, et al. (2021). Inhibitory effects of xanthine oxidase inhibitor, topiroxostat, on development of neuropathy in db/db mice. Neurobiology of Disease 155:105392. DOI: 10.1016/j.nbd.2021.105392 DOI: https://doi.org/10.1016/j.nbd.2021.105392
Published
How to Cite
Issue
Section
Copyright (c) 2025 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
